Ascendis Pharma Reports Second Quarter 2023 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/4/2026
- Wall Street ends sharply higher as Waller remarks ease rate hike fears
- Fed’s Waller open to September rate hold - if disinflation holds up
- Broadcom raises AI chip forecast as Big Tech keeps writing bigger checks
- Nvidia to acquire AI platform Hugging Face in landmark $12.9B deal
- Tesla to unveil Cybercab Texas today, details are few
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Ascendis Pharma (ASND) Tops Q2 EPS by EUR 37c, Beats on Revenue; Offers FY23 Revenue Guidance
September 5, 2023 4:04 PM EDTAscendis Pharma (NASDAQ: ASND) reported Q2 EPS of (EUR2.16), EUR0.37 better than the analyst estimate of (EUR2.53). Revenue for the quarter came in at EUR47.4 million versus the consensus estimate of EUR37.37 million.
GUIDANCE:
Ascendis Pharma sees FY2023 revenue... More
